№ lp_2_3_11327
File format: docx
Character count: 124491
File size: 152 KB
Year:
2025
Region / city:
United States, Washington D.C.
Subject:
Financial Reporting
Document Type:
Quarterly Report
Organization / institution:
U.S. Securities and Exchange Commission
Author:
Eli Lilly and Company
Target audience:
Investors, Financial Analysts
Period of validity:
Quarter ending September 30, 2025
Approval Date:
Not specified
Date of changes:
Not specified
Description:
Financial report detailing the financial status, results of operations, and other corporate disclosures for Eli Lilly and Company for the third quarter of 2025.
Price: 8 / 10 USD
The file will be delivered to the email address provided at checkout within 12 hours.
The file will be delivered to the email address provided at checkout within 12 hours.
Don’t have cryptocurrency yet?
You can still complete your purchase in a few minutes:- Buy Crypto in a trusted app (Coinbase, Kraken, Cash App or any similar service).
- In the app, tap Send.
- Select network, paste our wallet address.
- Send the exact amount shown above.
The final amount may vary slightly depending on the payment method.
The file will be sent to the email address provided at checkout within 24 hours.
The product description is provided for reference. Actual content and formatting may differ slightly.
Year:
2024
Region / city:
Delaware, USA
Theme:
Business operations, financial report
Document type:
Annual report
Institution:
U.S. Securities and Exchange Commission
Author:
BAB, Inc.
Target audience:
Investors, financial analysts, regulators
Period of validity:
Fiscal year ending November 30, 2024
Approval date:
Not specified
Date of amendments:
Not specified
Year:
2025
Region / City:
Thousand Oaks, California
Topic:
Financial Report
Document Type:
Quarterly Report
Organization:
Amgen Inc.
Author:
Amgen Inc.
Target Audience:
Investors, Financial Analysts
Period of Validity:
Quarter ended June 30, 2025
Approval Date:
Not specified
Date of Changes:
Not specified
Context Description:
Financial report for Amgen Inc., filed in accordance with the Securities Exchange Act of 1934.
Year:
2015
Region / City:
Bethesda, Maryland
Topic:
Corporate Annual Report
Document Type:
Report
Organization:
Lockheed Martin Corporation
Author:
Lockheed Martin Corporation
Target Audience:
Investors, regulators, stakeholders
Effective Period:
Fiscal year 2015
Date of Approval:
N/A
Date of Modifications:
N/A
Year:
2020
Region / City:
Foster City, California
Topic:
Financial report
Document type:
Annual report
Organization / Institution:
Vaxcyte, Inc.
Author:
Vaxcyte, Inc.
Target Audience:
Investors, analysts, regulatory authorities
Period of Validity:
2020 fiscal year
Approval Date:
N/A
Date of Amendments:
N/A
Year:
2026
Region / city:
South San Francisco, California
Subject:
Nasdaq Listing Compliance
Document Type:
Official report
Organization:
Vistagen Therapeutics, Inc.
Author:
Shawn K. Singh
Target audience:
Shareholders, Investors, Financial regulators
Period of validity:
February 3, 2026 – August 6, 2026
Date of approval:
February 6, 2026
Date of amendments:
None
Contextual description:
Report outlining a notice from Nasdaq regarding Vistagen Therapeutics’ non-compliance with listing requirements based on bid price for its common stock.
Year:
2024
Region / City:
United States / Washington, D.C.
Subject:
Financial Reporting
Document Type:
Annual Report
Organization / Institution:
Certara, Inc.
Author:
Certara, Inc.
Target Audience:
Investors, Securities Regulators
Effective Period:
Fiscal Year 2024
Approval Date:
Not specified
Amendment Date:
Not specified
Description:
Form 10-K annual report detailing Certara, Inc.’s financial and operational performance for the fiscal year ended December 31, 2024.
Issuer:
H&R Block, Inc.
Form:
Form 10-Q
Reporting Period:
Quarterly period ended September 30, 2025
Fiscal Period:
Q1 FY2026
Regulatory Authority:
United States Securities and Exchange Commission
Governing Law:
Securities Exchange Act of 1934
Commission File Number:
1-06089
State of Incorporation:
Missouri
Principal Executive Offices:
One H&R Block Way, Kansas City, Missouri 64105
Telephone:
(816) 854-3000
Stock Exchange:
New York Stock Exchange
Trading Symbol:
HRB
Security Registered:
Common Stock, without par value
Shares Outstanding as of October 31, 2025:
126,425,305 shares
Filing Type:
Quarterly Report
Financial Data Status:
Unaudited
Year:
2025
Region / City:
Thousand Oaks, California
Topic:
Financial Report
Document Type:
Quarterly Report
Organization:
Amgen Inc.
Author:
Amgen Inc.
Target Audience:
Investors, Financial Analysts
Period of Validity:
Quarter ended June 30, 2025
Approval Date:
Not specified
Date of Changes:
Not specified
Context Description:
Financial report for Amgen Inc., filed in accordance with the Securities Exchange Act of 1934.
Year:
2014
Reporting Period:
Quarterly period ended September 30, 2014
Document Type:
Form 10-Q Quarterly Report
Regulatory Framework:
Securities Exchange Act of 1934 (Section 13 or 15(d))
Commission File Number:
1-32630
Company:
Fidelity National Financial, Inc.
State of Incorporation:
Delaware
I.R.S. Employer Identification Number:
16-1725106
Principal Executive Offices:
601 Riverside Avenue, Jacksonville, Florida 32204
Telephone:
(904) 854-8100
Shares Outstanding as of October 31, 2014:
FNF Group Common Stock – 277,907,550; FNFV Group Common Stock – 92,944,570
Financial Statements Included:
Condensed Consolidated Balance Sheets; Statements of Earnings; Statements of Comprehensive Earnings; Statement of Equity; Statements of Cash Flows; Notes to Condensed Consolidated Financial Statements
Reporting Currency:
United States Dollars (in millions, except share data)
Audited Status:
Unaudited (interim financial statements)
Year:
2024
Reporting period end date:
September 30, 2024
Country:
United States
City:
Washington, DC
Document type:
Quarterly report (Form 10-Q)
Organization:
United States Securities and Exchange Commission
Reporting company:
Fiserv, Inc.
State of incorporation:
Wisconsin
Headquarters address:
600 N. Vel R. Phillips Avenue, Milwaukee, WI 53203, United States
Telephone:
(262) 879-5000
SEC file number:
1-38962
Stock exchange:
New York Stock Exchange
Trading symbol:
FI
Document sections:
Financial statements, Management’s Discussion and Analysis, Market Risk Disclosures, Controls and Procedures, Legal Proceedings, Exhibits
Financial statement scope:
Consolidated financial statements (unaudited)
Shares outstanding date:
October 18, 2024
Shares outstanding:
568,918,735 shares of common stock
Year:
2012
Company:
HEICO Corporation
State of Incorporation:
Florida
Commission File Number:
1-4604
Type of Document:
SEC Form 10-Q Quarterly Report
Period Covered:
October 31, 2011 – January 31, 2012
Address:
3000 Taft Street, Hollywood, Florida, 33021
Telephone:
(954) 987-4000
Number of Shares Outstanding:
Common Stock 17,057,339; Class A Common Stock 25,052,644
Financial Information Included:
Condensed Consolidated Balance Sheets, Statements of Operations, Shareholders’ Equity, Comprehensive Income, Cash Flows, Notes, Management Discussion and Analysis
Filing Status:
Large accelerated filer, not a shell company
Year:
2025
Jurisdiction:
Cayman Islands
Company:
GigCapital8 Corp.
Document Type:
SEC Form 10-Q
Securities Exchange:
Nasdaq Stock Market LLC
Ticker Symbols:
GIW, GIWWU, GIWWR
Filing Number:
001-42893
Share Classes:
Class A ordinary shares, Class B ordinary shares, Units, Rights
Number of Shares Outstanding:
25,657,625 Class A, 10,814,432 Class B as of November 6, 2025
Accounting Period:
Quarterly
Financial Statements Included:
Condensed Balance Sheet, Condensed Statements of Operations and Comprehensive Loss, Condensed Statements of Shareholders’ Deficit, Condensed Statement of Cash Flows
Additional Notes:
Unaudited financial statements, Emerging growth company, Smaller reporting company
Contact:
1731 Embarcadero Rd., Suite 200, Palo Alto, CA 94303, Tel: (650) 276-7040
Agency:
United States Securities and Exchange Commission
Form number:
Form 25
Document type:
Regulatory filing form
Jurisdiction:
United States
Legal basis:
Securities Exchange Act of 1934
Applicable rules:
Rule 12d2-2 (17 CFR 240.12d2-2); Rule 19d-1 (17 CFR 240.19d-1)
OMB control number:
3235-0080
OMB expiration date:
March 31, 2021
Filing system:
EDGAR
Effective delisting period:
10 days after filing
Effective withdrawal of registration period:
90 days after filing
Revision identifier:
SEC 1654 (03-06)
Year:
2021
Region / city:
Panama City, Republic of Panama
Topic:
Financial Report
Document Type:
Press Release
Organization:
Banco Latinoamericano de Comercio Exterior, S.A.
Author:
Bladex Communications
Target Audience:
Investors, financial analysts
Period of validity:
Q2 2021, 6M 2021
Approval Date:
July 29, 2021
Date of Changes:
None
Year:
2024
Region / city:
Delaware, USA
Theme:
Business operations, financial report
Document type:
Annual report
Institution:
U.S. Securities and Exchange Commission
Author:
BAB, Inc.
Target audience:
Investors, financial analysts, regulators
Period of validity:
Fiscal year ending November 30, 2024
Approval date:
Not specified
Date of amendments:
Not specified
Document type:
Regulatory compliance checklist
Governing law:
Securities Exchange Act of 1934
Applicable rules:
SEA Rules 17a-3 and 17a-4
Regulatory authority:
U.S. Securities and Exchange Commission
Related organization:
Financial Industry Regulatory Authority
Subject matter:
Broker-dealer books and records requirements
Jurisdiction:
United States
Retention periods:
Three to six years depending on record type
Target entities:
Registered broker-dealers
Source references:
SEA Rule 17a-3; SEA Rule 17a-4
Compliance focus:
Record creation and retention
Year:
2022
Region / City:
Panama City, Republic of Panama
Topic:
Foreign trade, financial reporting
Document Type:
Report
Organization:
Banco Latinoamericano de Comercio Exterior, S.A.
Author:
Ana Graciela de Méndez
Target Audience:
Investors, financial institutions
Period of Validity:
April 2022
Approval Date:
April 28, 2022
Date of Changes:
April 28, 2022
Contextual Description:
A financial report by Banco Latinoamericano de Comercio Exterior, S.A. detailing the submission of their annual report on Form 20-F to the U.S. Securities and Exchange Commission for the fiscal year 2021.
Year:
2025
Region / City:
Thousand Oaks, California
Topic:
Financial Report
Document Type:
Quarterly Report
Organization:
Amgen Inc.
Author:
Amgen Inc.
Target Audience:
Investors, Financial Analysts
Period of Validity:
Quarter ended June 30, 2025
Approval Date:
Not specified
Date of Changes:
Not specified
Context Description:
Financial report for Amgen Inc., filed in accordance with the Securities Exchange Act of 1934.
Year:
2025
Date of Event Which Requires Filing of this Statement:
October 31, 2025
Amendment Number:
3
Issuing Authority:
Securities and Exchange Commission
Type of Document:
Schedule 13G filing
Governing Law:
Securities Exchange Act of 1934
Issuer:
Praxis Precision Medicines, Inc.
Issuer Address:
99 High Street, 30th Floor, Boston, MA 02110
Title of Class of Securities:
Common Stock, par value $0.0001 per share
CUSIP Number:
74006W207
Outstanding Shares Referenced:
24,693,005
Reporting Persons:
Adage Capital Management, L.P.; Robert Atchinson; Phillip Gross
Place of Organization:
Delaware
Citizenship:
United States
Business Address of Reporting Persons:
200 Clarendon Street, 52nd Floor, Boston, Massachusetts 02116
Aggregate Amount Beneficially Owned:
1,305,175 shares
Percent of Class Represented:
5.29%
Filing Category:
Rule 13d-1
SEC File References:
Prospectus filed pursuant to Rule 424(b)(5) on October 20, 2025; Current Report on Form 8-K filed October 20, 2025
Year:
2015
Region / City:
Bethesda, Maryland
Topic:
Corporate Annual Report
Document Type:
Report
Organization:
Lockheed Martin Corporation
Author:
Lockheed Martin Corporation
Target Audience:
Investors, regulators, stakeholders
Effective Period:
Fiscal year 2015
Date of Approval:
N/A
Date of Modifications:
N/A